Cardiometabolic Disorders News

SEATTLE — Among men aged at least 40 years who experienced a fracture, most with subsequent fractures in the next 2 years had cardiometabolic comorbidities and used medications linked to increased fall risk, according to researchers.

The FDA expanded an indication for the SGLT2 inhibitor dapagliflozin to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction, according to an industry press release.

Kidney disease does not influence the benefits of the SGLT2 inhibitor empagliflozin on major HF events, even in patients at high renal risk, according to a new analysis of the EMPEROR-Pooled study.

Type 2 diabetes and atherosclerotic CVD risk varies considerably among Asian American subgroups and clinical trials assessing interventions must reflect the disparities within the Asian American population, researchers reported.

SEATTLE — Adults with diabetes who used a GLP-1 receptor agonist after undergoing kidney transplantation had a decline in BMI and more stable measures of kidney function than those who did not use a GLP-1, according to a speaker.

SEATTLE — Providers treating people with type 2 diabetes should take a complication-centric approach for determining first-line pharmacotherapy, according to a consensus statement.

SEATTLE — The rate of deaths attributed to vascular complications increased from 2001 to 2020 for adults with diabetes in the U.S., with the rise mainly due to an increase in deaths from diabetic nephropathy, according to a speaker.

Dietary patterns focused on eating more whole grains, vegetables, fruits, legumes, nuts and seeds are best for the management of diabetes, according to an updated guideline published in Diabetologia.

Treatment with the melanocortin-4 receptor agonist setmelanotide reduced hyperphagia and led to improvements in emotional well-being among children and adults with Bardet-Biedl syndrome, according to study findings.

Adults with overweight or obesity and type 2 diabetes achieved a mean weight loss of more than 13% after taking either 10 mg or 15 mg of tirzepatide for 72 weeks, according to topline results from the SURMOUNT-2 trial.